Jeffrey Parvin, MD, PhD
Leadership Title: Louis Levy Professorship for Cancer
Academic Title: Professor in the College of Medicine
Research Program: Cancer Biology
About Me
More info forI am the Louis Levy Professor for Cancer and a member of the Cancer Biology Program at the OSUCCC – James, where my research focuses on biological processes in breast cancer.
In particular, I investigate the pathways regulated by the BRCA1 tumor-suppressor proteins, as well as the processes involved in DNA damage repair, transcription of mRNA and epigenetics.
I recently developed a high-throughput technology for interpreting the functional effects of missense variants, while another one of my studies analyzed the DNA repair function of over 1,000 variants of the BRCA1 protein.
I have co-authored many articles in well-respected publications, including Nucleic Acids Research, Human Mutation, Genetics, and Cancer Biology & Therapy.
Research Interests
More info for- Neoplasms
- DNA Damage
- DNA Breaks, Double-Stranded
- Breast Neoplasms
- Ovarian Neoplasms
Academic Office & Contact Information
More info forAcademic Office:
Biomedical Research Tower 0904
460 W 12th Ave
Columbus, Ohio 43210-2210Phone:
614-292-0523Email:
parvin.4@osu.eduPublications
More info forAugust 14, 2023DNA repair function scores for 2172 variants in the BRCA1 amino-terminus.
Diabate M, Islam MM, Nagy G, Banerjee T, Dhar S, Smith N, Adamovich AI, Starita LM, Parvin JD
PLoS Genet
January 1, 2023Multiplexed assay of variant effect reveals residues of functional importance in the BRCA1 coiled-coil and serine cluster domains.
Nagy G, Diabate M, Banerjee T, Adamovich AI, Smith N, Jeon H, Dhar S, Liu W, Burgess K, Chung D, Starita LM, Parvin JD
PLoS One
February 10, 2022The functional impact of BRCA1 BRCT domain variants using multiplexed DNA double-strand break repair assays.
Adamovich AI, Diabate M, Banerjee T, Nagy G, Smith N, Duncan K, Mendoza Mendoza E, Prida G, Freitas MA, Starita LM, Parvin JD
Am J Hum Genet
January 1, 2021Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Moustafa D, Elwahed MRA, Elsaid HH, Parvin JD
PLoS One